Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced on Thursday that it has named Henry Pelish, PhD as its new chief scientific officer.

In the new role, Dr Pelish is to continue to manage discovery and early-stage development activities.

Dr Pelish joined as Biology lead in 2018, managing the discovery and early-stage development of zidesamtinib, NVL-655 and NVL-330 and ongoing research and discovery efforts. He has more than 15 years of experience in cancer biology, chemical biology and organic chemistry.

Dr Pelish, said, 'The opportunity to take part in building Nuvalent from the ground up has been one of the most rewarding experiences of my career. From the outset, our efforts have focused on solving for the limitations of existing therapies, and I am encouraged by all we have been able to achieve thus far. I look forward to continuing to work with my highly dedicated colleagues towards our goal of delivering tangible benefits to patients with cancer.'